Sarepta Therapeutics SRPT is the market leader in the Duchenne muscular dystrophy (DMD) space. It currently markets four ...
Sarepta's future looks a lot more promising now that it's obtained label expansion for Elevidys. And with more therapies and ...
The unilateral decision by Peter Marks, a top FDA official, to approve a gene therapy for Duchenne muscular dystrophy looks ...
Let's look at one corporation that has performed extremely well this year, but still looks like an excellent pick to hold ...
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems.
The stock price of Sarepta Therapeutics, a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, was up 30% on ...
Sarepta Therapeutics SRPT has outperformed the market over the past 10 years by 8.61% on an annualized basis producing an ...
Sarepta Therapeutics always wins. That was a given, even before the Food and Drug Administration expanded approval of the company’s Duchenne muscular dystrophy drug on Thursday. Will boys with ...
Citigroup raised the price target for the Sarepta Therapeutics Inc (NASDAQ:SRPT) stock from “a Buy” to “a Neutral”. The rating was released on June 26, 2024, according to finviz. The research report ...
Sarepta stock plunged last year after data from a confirmatory trial of its gene therapy disappointed investors Given the high demand and acceptable safety, analysts flagged manufacturing concerns ...
Sarepta Therapeutics Inc.’s stock soared 38% in premarket trade Friday, after the biotech said the U.S. regulator has approved an expanded indication of its treatment for the rare muscle ...
Here are the five things you need to know, including the latest on Sarepta, possible changes at the FDA, real estate disputes, and the best time to be a soccer fan. Good morning, Boston.